SCHEMBL327599

SCHEMBL327599

N#Cc1ccc2cc(C(=O)O)[nH]c2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 2/20 0.55
HSD17B10 Q99714 4/20 0.54
KDM4E B2RXH2 3/20 0.54
HPGD P15428 3/20 0.54
MAPT P10636 1/20 0.54
DAO P14920 1/20 0.54
SRD5A2 P31213 1/20 0.54
EIF4A3 P38919 1/20 0.54
GPR35 Q9HC97 1/20 0.50
SMAD3 P84022 1/20 0.47
ALDH1A1 P00352 3/20 0.46
LMNA P02545 2/20 0.46
F7 P08709 1/20 0.46
F3 P13726 1/20 0.46
PDPK1 O15530 1/20 0.46
TSHR P16473 1/20 0.46
NFKB1 P19838 1/20 0.46
APEX1 P27695 1/20 0.46
CYP2C19 P33261 1/20 0.46
TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30180579 1.00 PIN1 (0.55) PIN1HSD17B10KDM4EHPGDMAPT
SCHEMBL30071246 0.88 EIF4A3 (0.49) PIN1HSD17B10KDM4EHPGDMAPT
SCHEMBL20494469 0.88 EIF4A3 (0.49) PIN1HSD17B10KDM4EHPGDMAPT
SCHEMBL1609672 0.87 SMAD3 (0.60) PIN1HSD17B10KDM4EHPGDMAPT
SCHEMBL1615302 0.85 PIN1 (0.47) PIN1EIF4A3FGFR1FGFR2FGFR3
SCHEMBL30310494 0.81 XDH (0.46) PIN1HSD17B10KDM4EHPGDALDH1A1
SCHEMBL1307519 0.81 XDH (0.46) PIN1HSD17B10KDM4EHPGDALDH1A1
Alcohol SCHEMBL27477859 0.80 KDM4E (0.55) PIN1HSD17B10KDM4EHPGDMAPT
SCHEMBL10066494 0.79 ITK (0.45) PIN1EIF4A3FGFR1FGFR2FGFR3
SCHEMBL24019828 0.78 ALOX15 (0.65) PIN1KDM4EMAPTEIF4A3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116857-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS PARDES BIOSCIENCES INC (US) 2026-04-30 US disclosed
EP-3860636-B1 MATRIPTASE 2 INHIBITORS AND USES THEREOF DISC MEDICINE INC (US) 2026-01-28 EP disclosed
US-12428415-B2 Matriptase 2 inhibitors and uses thereof DISC MEDICINE, INC. (US) 2025-09-30 US disclosed
WO-2025087365-A1 METTL3 INHIBITOR 杭州邦顺制药有限公司 2025-05-01 WO disclosed
US-20250122195-A1 POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS STORM THERAPEUTICS LIMITED (GB) 2025-04-17 US disclosed
US-12195458-B2 Polyheterocyclic compounds as METTL3 inhibitors STORM THERAPEUTICS LIMITED (GB) 2025-01-14 US disclosed
US-12145911-B2 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2024-11-19 US disclosed
US-20240270693-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. (US) 2024-08-15 US disclosed
CN-116685576-A Cysteine protease inhibitors and methods of use thereof 美商帕迪斯生物科学公司 2023-09-01 CN disclosed
US-11725010-B2 Polyheterocyclic compounds as METTL3 inhibitors STORM THERAPEUTICS LIMITED (GB) 2023-08-15 US disclosed
EP-0983244-A1 TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS SMITHKLINE BEECHAM PLC (GB) 2000-03-08 EP disclosed
CN-1219932-A Aromatic amidine derivatives useful as selective thrombin inhibitors C & C RESEARCH LAB (KR) 1999-06-16 CN disclosed
WO-1998050364-A1 TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS SMITHKLINE BEECHAM PLC (GB) 1998-11-12 WO disclosed
EP-0622356-B1 Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange SUMITOMO PHARMA (JP) 1998-07-01 EP disclosed
US-5753670-A ANTICOAGULANTS THE GREEN CROSS CORPORATION (JP) 1998-05-19 US disclosed
US-5635527-A ANTAGONIST OF PLATELET MEMBRANE GLYCOPROTEIN; TREATMENT OF THROMBOTIC DISEASES THE GREEN CROSS CORPORATION (JP) 1997-06-03 US disclosed
EP-0712844-A1 NOVEL FUSED-RING CARBOXYLIC ACID COMPOUND OR SALT THEREOF, AND MEDICINAL USE THEREOF THE GREEN CROSS CORPORATION (JP) 1996-05-22 EP disclosed
EP-0708091-A2 Indoloylguanidine derivatives SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1996-04-24 EP disclosed
EP-0655439-A2 5,6-Bicyclic glycoprotein IIb IIIa antagonists useful in inhibition of platelet aggregation ELI LILLY AND COMPANY (US) 1995-05-31 EP disclosed
EP-0622356-A1 Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1994-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12428415-B2 Matriptase 2 inhibitors and uses thereof MMP7, MATR3, SPINT2 PIN1 402/4885HSD17B10 1143/4885KDM4E 1948/4885
US-20260116857-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS CTRC, CTRL, CTSL PIN1 2499/4885HSD17B10 856/4885KDM4E 2746/4885
US-20250122195-A1 POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS METTL3, DIMT1, TPMT PIN1 1082/4885HSD17B10 3258/4885KDM4E 107/4885
US-20240270693-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSV, CTSL PIN1 267/4885HSD17B10 1711/4885KDM4E 2930/4885
US-11725010-B2 Polyheterocyclic compounds as METTL3 inhibitors METTL3, DIMT1, TPMT PIN1 1082/4885HSD17B10 3258/4885KDM4E 107/4885
US-12195458-B2 Polyheterocyclic compounds as METTL3 inhibitors METTL3, DIMT1, TPMT PIN1 1082/4885HSD17B10 3258/4885KDM4E 107/4885
US-12145911-B2 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL PIN1 267/4885HSD17B10 1711/4885KDM4E 2930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.